Amylyx Pharmaceuticals IncNASDAQ:AMLX
- LAST PRICE1.8700
- TODAY'S CHANGE (%)0.0500 (2.7473%)
- Bid / Lots1.8700/ 7
- Ask / Lots1.8900/ 11
- Open / Previous Close1.8300 / 1.8200
- Day Range
- 52 Week Range
- Volume1,572,136
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AMLX |
|---|---|---|
| 09:32 ET | 31458 | 1.865 |
| 09:34 ET | 31684 | 1.905 |
| 09:36 ET | 14568 | 1.91 |
| 09:38 ET | 21610 | 1.9 |
| 09:39 ET | 41546 | 1.93 |
| 09:41 ET | 16274 | 1.9395 |
| 09:43 ET | 4723 | 1.94 |
| 09:45 ET | 30319 | 1.92 |
| 09:48 ET | 21140 | 1.895 |
| 09:50 ET | 26474 | 1.905 |
| 09:52 ET | 18292 | 1.9 |
| 09:54 ET | 46861 | 1.87 |
| 09:56 ET | 8087 | 1.87 |
| 09:57 ET | 10579 | 1.88 |
| 09:59 ET | 21987 | 1.88 |
| 10:01 ET | 17408 | 1.89 |
| 10:03 ET | 11136 | 1.89 |
| 10:06 ET | 493 | 1.89 |
| 10:08 ET | 12995 | 1.885 |
| 10:10 ET | 6011 | 1.89 |
| 10:12 ET | 2625 | 1.885 |
| 10:14 ET | 1411 | 1.89 |
| 10:15 ET | 3600 | 1.89 |
| 10:17 ET | 1800 | 1.89 |
| 10:19 ET | 8247 | 1.9 |
| 10:21 ET | 5130 | 1.89 |
| 10:24 ET | 9307 | 1.88 |
| 10:26 ET | 9414 | 1.875 |
| 10:28 ET | 600 | 1.875 |
| 10:30 ET | 3033 | 1.87 |
| 10:32 ET | 3265 | 1.875 |
| 10:33 ET | 14850 | 1.89 |
| 10:35 ET | 867 | 1.88 |
| 10:37 ET | 563 | 1.8893 |
| 10:39 ET | 2090 | 1.89 |
| 10:42 ET | 450 | 1.89 |
| 10:44 ET | 1404 | 1.8821 |
| 10:46 ET | 1580 | 1.88 |
| 10:48 ET | 3942 | 1.885 |
| 10:50 ET | 1900 | 1.88 |
| 10:51 ET | 3022 | 1.89 |
| 10:53 ET | 3533 | 1.89 |
| 10:55 ET | 13507 | 1.895 |
| 10:57 ET | 4746 | 1.9 |
| 11:00 ET | 32590 | 1.905 |
| 11:02 ET | 2027 | 1.905 |
| 11:04 ET | 6172 | 1.9075 |
| 11:06 ET | 9493 | 1.894 |
| 11:08 ET | 1631 | 1.89 |
| 11:09 ET | 33058 | 1.8897 |
| 11:11 ET | 2452 | 1.88 |
| 11:13 ET | 2659 | 1.88 |
| 11:15 ET | 1489 | 1.88 |
| 11:18 ET | 2809 | 1.88 |
| 11:20 ET | 1200 | 1.88 |
| 11:22 ET | 2033 | 1.88 |
| 11:24 ET | 1000 | 1.88 |
| 11:26 ET | 1022 | 1.885 |
| 11:27 ET | 408 | 1.885 |
| 11:29 ET | 4212 | 1.88 |
| 11:31 ET | 3539 | 1.885 |
| 11:33 ET | 1704 | 1.89 |
| 11:36 ET | 3658 | 1.885 |
| 11:38 ET | 2000 | 1.88 |
| 11:40 ET | 2473 | 1.885 |
| 11:42 ET | 550 | 1.885 |
| 11:44 ET | 1805 | 1.89 |
| 11:45 ET | 38180 | 1.86 |
| 11:47 ET | 6328 | 1.865 |
| 11:49 ET | 1049 | 1.86 |
| 11:51 ET | 1300 | 1.855 |
| 11:54 ET | 922 | 1.86 |
| 11:56 ET | 4293 | 1.8594 |
| 11:58 ET | 13650 | 1.87 |
| 12:00 ET | 900 | 1.87 |
| 12:02 ET | 8540 | 1.865 |
| 12:03 ET | 5200 | 1.865 |
| 12:05 ET | 306 | 1.865 |
| 12:07 ET | 3476 | 1.86 |
| 12:09 ET | 1100 | 1.865 |
| 12:12 ET | 1152 | 1.87 |
| 12:14 ET | 1173 | 1.86 |
| 12:16 ET | 3716 | 1.86 |
| 12:18 ET | 3743 | 1.86 |
| 12:20 ET | 304 | 1.855 |
| 12:21 ET | 8385 | 1.86 |
| 12:23 ET | 1650 | 1.86 |
| 12:25 ET | 3127 | 1.86 |
| 12:27 ET | 7029 | 1.865 |
| 12:30 ET | 400 | 1.865 |
| 12:32 ET | 100 | 1.87 |
| 12:34 ET | 1802 | 1.87 |
| 12:36 ET | 200 | 1.87 |
| 12:38 ET | 702 | 1.865 |
| 12:39 ET | 702 | 1.87 |
| 12:41 ET | 700 | 1.865 |
| 12:43 ET | 1917 | 1.87 |
| 12:45 ET | 700 | 1.87 |
| 12:48 ET | 400 | 1.86 |
| 12:50 ET | 800 | 1.865 |
| 12:52 ET | 2684 | 1.865 |
| 12:54 ET | 6947 | 1.865 |
| 12:56 ET | 1897 | 1.8675 |
| 12:57 ET | 350 | 1.8609 |
| 12:59 ET | 605 | 1.86 |
| 01:01 ET | 4900 | 1.86 |
| 01:03 ET | 600 | 1.86 |
| 01:06 ET | 9491 | 1.865 |
| 01:08 ET | 600 | 1.865 |
| 01:10 ET | 1260 | 1.865 |
| 01:12 ET | 600 | 1.86 |
| 01:14 ET | 900 | 1.86 |
| 01:15 ET | 600 | 1.86 |
| 01:17 ET | 1830 | 1.86 |
| 01:19 ET | 1619 | 1.86 |
| 01:21 ET | 11604 | 1.865 |
| 01:24 ET | 6310 | 1.865 |
| 01:26 ET | 1818 | 1.86 |
| 01:28 ET | 1000 | 1.86 |
| 01:30 ET | 1172 | 1.86 |
| 01:32 ET | 1414 | 1.86 |
| 01:33 ET | 4711 | 1.8607 |
| 01:35 ET | 2453 | 1.86 |
| 01:37 ET | 900 | 1.86 |
| 01:39 ET | 6755 | 1.865 |
| 01:42 ET | 1270 | 1.86 |
| 01:44 ET | 824 | 1.86 |
| 01:46 ET | 1290 | 1.86 |
| 01:48 ET | 12969 | 1.865 |
| 01:50 ET | 1700 | 1.86 |
| 01:51 ET | 1400 | 1.86 |
| 01:53 ET | 2260 | 1.86 |
| 01:55 ET | 11373 | 1.86 |
| 01:57 ET | 17200 | 1.865 |
| 02:00 ET | 1763 | 1.8675 |
| 02:02 ET | 1900 | 1.86 |
| 02:04 ET | 3149 | 1.86 |
| 02:06 ET | 1004 | 1.865 |
| 02:08 ET | 8500 | 1.86 |
| 02:09 ET | 1425 | 1.86 |
| 02:11 ET | 1777 | 1.86 |
| 02:13 ET | 621 | 1.86 |
| 02:15 ET | 800 | 1.86 |
| 02:18 ET | 800 | 1.86 |
| 02:20 ET | 1231 | 1.8675 |
| 02:22 ET | 800 | 1.86 |
| 02:24 ET | 701 | 1.8622 |
| 02:26 ET | 9857 | 1.865 |
| 02:27 ET | 2831 | 1.86 |
| 02:29 ET | 1367 | 1.86 |
| 02:31 ET | 2600 | 1.86 |
| 02:33 ET | 4095 | 1.865 |
| 02:36 ET | 987 | 1.8697 |
| 02:38 ET | 300 | 1.86 |
| 02:40 ET | 1500 | 1.86 |
| 02:42 ET | 2000 | 1.87 |
| 02:44 ET | 800 | 1.865 |
| 02:45 ET | 1600 | 1.86 |
| 02:47 ET | 600 | 1.86 |
| 02:49 ET | 700 | 1.8693 |
| 02:51 ET | 1807 | 1.8693 |
| 02:54 ET | 49790 | 1.89 |
| 02:56 ET | 600 | 1.89 |
| 02:58 ET | 480 | 1.885 |
| 03:00 ET | 4017 | 1.89 |
| 03:02 ET | 1351 | 1.88 |
| 03:03 ET | 17492 | 1.885 |
| 03:05 ET | 2943 | 1.88 |
| 03:07 ET | 1071 | 1.8888 |
| 03:09 ET | 714 | 1.88 |
| 03:12 ET | 500 | 1.88 |
| 03:14 ET | 9748 | 1.88 |
| 03:16 ET | 5134 | 1.87 |
| 03:18 ET | 6556 | 1.87 |
| 03:20 ET | 3470 | 1.8792 |
| 03:21 ET | 600 | 1.87 |
| 03:23 ET | 600 | 1.87 |
| 03:25 ET | 1619 | 1.875 |
| 03:27 ET | 1008 | 1.87 |
| 03:30 ET | 2504 | 1.87 |
| 03:32 ET | 1100 | 1.87 |
| 03:34 ET | 1500 | 1.87 |
| 03:36 ET | 2186 | 1.87 |
| 03:38 ET | 2443 | 1.87 |
| 03:39 ET | 7518 | 1.87 |
| 03:41 ET | 22171 | 1.86 |
| 03:43 ET | 1866 | 1.865 |
| 03:45 ET | 1933 | 1.86 |
| 03:48 ET | 3752 | 1.86 |
| 03:50 ET | 5264 | 1.865 |
| 03:52 ET | 44460 | 1.885 |
| 03:54 ET | 26446 | 1.885 |
| 03:56 ET | 28639 | 1.875 |
| 03:57 ET | 40288 | 1.865 |
| 03:59 ET | 205268 | 1.87 |
Today
DJ Amylyx Pharmaceuticals Is Maintained at Neutral by Mizuho, from 16 hours ago by Dow Jones
16 hours ago by Dow Jones
May 10, 2024
DJ Amylyx Pharmaceuticals Price Target Maintained With a $8.00/Share by HC Wainwright & Co., from 8:35AM ET on Friday May 10, 2024 by Dow Jones
8:35AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Press Release: Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results, from 7:01AM ET on Thursday May 09, 2024 by Dow Jones
7:01AM ET on Thursday May 09, 2024 by Dow JonesAmylyx Pharmaceuticals Reports First Quarter 2024 Financial Results, from 7:00AM ET on Thursday May 09, 2024 by Dow Jones
7:00AM ET on Thursday May 09, 2024 by Dow Jones
May 8, 2024
Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference, from 9:00AM ET on Wednesday May 08, 2024 by Dow Jones
9:00AM ET on Wednesday May 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Amylyx Pharmaceuticals Inc | 123.8M | -1.8x | --- |
Organogenesis Holdings Inc | 392.4M | 65.4x | --- |
Amarin Corporation PLC | 378.0M | -7.1x | --- |
Coherus BioSciences Inc | 239.8M | -2.7x | --- |
Sinovac Biotech Ltd | 639.9M | -6.0x | --- |
Invitae Corp | 171.9K | 0.0x | --- |
Company Information
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS). RELYVRIO (also known as AMX0035), an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol is approved to treat ALS in adults in the United States. AMX0035 is a dual unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). Its development of antisense oligonucleotides (ASOs), including lead ASO AMX0114, which targets calpain-2 (CAPN2), a gene encoding calcium-dependent proteolytic enzyme which has been implicated in the pathogenesis of ALS and other neurodegenerative diseases.
Contact Information
- Headquarters
- 43 THORNDIKE STREETCAMBRIDGE, MA, United States 02141
- Phone
- 617-682-0917
- Fax
- 302-636-5454
Executives
- Chair of the Board of Directors
- George Milne
- Co-Chief Executive Officer, Director
- Joshua Cohen
- Co-Chief Executive Officer, Director
- Justin Klee
- Chief Financial Officer
- James Frates
- Chief Legal Officer and General Counsel
- Gina Mazzariello
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $123.8M |
|---|---|
Revenue (TTM) | $398.0M |
Shares Outstanding | 68.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.07 |
Book Value | $6.40 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 0.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -20.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
